Nexpowder Endoscopic Hemostasis System Cleared

October 4, 2022

Medtronic’s Nexpowder endoscopic hemostasis system has received clearance from the FDA for treating patients with upper gastrointestinal nonvariceal bleeding.  

The powder is sprayed through a catheter that has a propriety powder-coating technology that minimizes clogging while improving visibility and control.

Nexpowder forms a durable gel upon contact, with or without the presence of blood, which then degrades in one to three days, the company said.

Medtronic distributes the system as part of a global supply agreement with Korea-based Next Biomedical.

View today's stories